ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic alterations (GAs).

Bibliographic Details
Title:	ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic alterations (GAs).
Authors:	Jain, Rohit K., Ong, Faustine, Faltas, Bishoy Morris, Tagawa, Scott T., Jiang, Di Maria, Heiligh, Jazlyn, Naqvi, Syeda Mahrukh Hussnain, Kim, Youngchul, Pelosof, Lorraine Cheryl, Yang, Yuanquan, Graham, Laura, Arafat, Waddah, Synold, Timothy Walter, Chatwal, Monica Sheila, Zhang, Jingsong, Chadha, Jus, Sonpavde, Guru P.
Source:	Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p808-808, 242p
Database:	Supplemental Index

More Details
ISSN:	0732183X
DOI:	10.1200/JCO.2025.43.5_suppl.808
Published in:	Journal of Clinical Oncology
Language:	English